Dr. Linda Penns research provides key contributions towards our understanding of cancer biology. Her work has led to the identification of a new cancer target (H19), which is currently in commercial development, and she is exploring the clinical application of a group of drugs known as statins as cancer therapeutics. In addition, with 25 years of experience working on a protein known as Myc which serves as a key player in the development of cancer she has developed unique molecular tools that will allow her to provide key insights that advance the development of more effective, personalized cancer therapies.